Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 7/20 | 0.57 |
| ▸ | MGAM | O43451 | 6/20 | 0.57 |
| ▸ | SI | P14410 | 6/20 | 0.57 |
| ▸ | MGAM2 | Q2M2H8 | 6/20 | 0.57 |
| ▸ | PARP1 | P09874 | 3/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2491052 | 0.85 | ADORA1 (0.56) | ADORA1ADORA3PSMB8GAAMGAM | |
| SCHEMBL66295 | 0.83 | PSMB8 (0.59) | ADORA1ADORA3PSMB8GAAMGAM | |
| SCHEMBL4715207 | 0.80 | GAA (0.54) | ADORA1ADORA3PSMB8GAAMGAM | |
| SCHEMBL19643484 | 0.80 | PKN1 (0.61) | ADORA1ADORA3GAAMGAMSI | |
| SCHEMBL11739880 | 0.79 | PSMB8 (0.56) | ADORA1ADORA3PSMB8GAAMGAM | |
| SCHEMBL8265192 | 0.79 | PARP1 (0.59) | ADORA1ADORA3PSMB8GAAMGAM | |
| SCHEMBL1422525 | 0.79 | PSMB8 (0.56) | ADORA1ADORA3PSMB8GAAMGAM | |
| SCHEMBL31534795 | 0.79 | PSMB8 (0.56) | ADORA1ADORA3PSMB8GAAMGAM | |
| SCHEMBL215756 | 0.79 | NUDT1 (0.70) | ADORA1ADORA3PSMB8GAAMGAM | |
| SCHEMBL22452316 | 0.79 | HDAC6 (0.60) | ADORA1ADORA3GAAMGAMSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140100245-A1 | Antiviral Drugs for Treatment of Arenvirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2014-04-10 | — | — | US | claimed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | claimed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | claimed |
| US-20140100245-A1 | Antiviral Drugs for Treatment of Arenvirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100245-A1 | Antiviral Drugs for Treatment of Arenvirus Infection | HAVCR2, ZC3HAV1, SARS1 | ADORA1 2573/4885ADORA3 1503/4885PSMB8 3450/4885 |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | ZC3HAV1, EIF2AK2, SARS1 | ADORA1 3974/4885ADORA3 3059/4885PSMB8 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.